Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial in ... MarketWatch (press release) ... models have demonstrated PLX cells are also potentially effective for other ischemic and inflammatory indications such as heart disease, muscle injury, inflammatory bowel disease and radiation as an alternative to bone marrow transplantation. |
